Kolltan Pharmaceuticals develops therapeutic monoclonal antibodies for the treatment of cancer based on seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at Yale University. Dr. Schlessinger’s laboratory has characterized a novel molecular mechanism underlying activation of receptor tyrosine kinases (RTKs) providing, for the first time, a clear molecular explanation at atomic resolution for the oncogenic activity of mutations that have been identified in a variety of human cancers. Acquired by: Celldex Therapeutics